Details of the Drug

General Information of Drug (ID: DMWSA0V)

Drug Name
Patisiran
Synonyms Patisiran [INN]; Patisiran [USAN:INN]; UNII-50FKX8CB2Y; 50FKX8CB2Y; ALN-18328
Indication
Disease Entry ICD 11 Status REF
Amyloidosis 5D00 Approved [1]
Hereditary amyloidosis 5D00.2 Approved [2]
Amyloid cardiomyopathy 5D00.20 Phase 3 [3]
Transthyretin familial amyloid cardiomyopathy 5D00.20 Phase 3 [4]
Drug Type
siRNA drug
Sequence
>Subunit 1
GUAACCAAGAGUAUUCCAUTT
>Subunit 2
AUGGAAUACUCUUGGUUACTT
Structure 3D Structure is Not Available
3D MOL is unavailable 2D MOL
ADMET Property
Clearance
The total body clearance of drug is 3.0 +/- 2.5 mL/h/kg []
Elimination
The bulk of the drug is broken down by nucleases, and less than 1% is excreted through the urine []
Half-life
The concentration or amount of drug in body reduced by one-half in 3.2 +/- 1.8 days []
Metabolism
The drug is metabolized via nucleases []
Vd
The volume of distribution (Vd) of drug is 0.26 +/- 0.20 L/kg []
Cross-matching ID
DrugBank ID
DB14582
TTD ID
D02UYB

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Transthyretin messenger RNA (TTR mRNA) TTPOYU7 TTHY_HUMAN Not Available [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 210922.
2 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT01960348) APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.